1. Human Positive Coactivator 4 Affects the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma via the mTOR/P70s6k Signaling Pathway.
- Author
-
Su, Xingxing, Yang, Yishi, Ma, Le, Luo, Peng, Shen, Kaicheng, Dai, Haisu, Jiang, Yan, Shuai, Ling, Liu, Zhipeng, You, Jinshan, Min, Ke, Shi, Chunmeng, and Chen, Zhiyu
- Subjects
- *
CELL growth , *CELL cycle , *CELL proliferation , *ADENOCARCINOMA , *CELL communication , *CANCER cell growth - Abstract
Introduction: Pancreatic cancer is one of the deadliest cancers in the world, and pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of all cases. Human positive coactivator 4 (PC4) is a transcriptional coactivator that has been associated with the development and progression of several tumors. However, no studies investigated the potential role of PC4 in PDAC. Methods: We investigated PC4 expression in 81 PDAC tissue samples using immunohistochemistry and studied the impact of PC4 expression and the molecular mechanisms of this altered expression on PDAC tumorigenesis and proliferation both in vitro and in vivo. Results: PC4 overexpression was correlated with a poor outcome in PDAC patients. The RNAi-mediated knockdown of PC4 expression in CFPAC-1 and AsPC-1 cell lines reduced cell proliferation and tumor growth. The loss of PC4 in PDAC inhibits cell growth by inducing cell cycle arrest at the G1/S transition and suppressing the mTOR/p70s6k pathway. Discussion/Conclusion: Our findings reveal for the first time that PC4 exerts oncogenic functions by activating mTOR/p70s6k signaling pathway-mediated cell proliferation, implying that PC4 is a promising therapeutic target for PDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF